Stockwinners Market Radar for May 22, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT Cathie Wood's ARK Investment bought 285K shares of Palantir today

18:41 EDT Toast CEO sells $3.36M in common stock - In a regulatory filing, Toast disclosed that its CEO Christopher Comparato sold 162.3K shares of common stock on May 19th in a total transaction size of $3.36M.

18:25 EDT Skyworks CEO: The opportunity for us is 'vibrant and compelling' - In an interview on CNBC's Mad Money, Liam Griffin said he's seeing a slowdown right now, but it's baked into the company's guidance. He expects to come out of this cycle stronger than before. Long term, the opportunity is "connecting the unconnected," he noted, particularly in India. He expects A.I. will generate tremendous processing power, which is great for Skyworks because it knows how to make it work. Griffin noted that the company has strong cash generation which will continue to drive upside for shareholders.

18:01 EDT Lilium signs agreement with Air-Dynamic to serve Switzerland and Italy - Lilium N.V. announced an agreement with Air-Dynamic SA, a Switzerland-based private jet and helicopter company. The firm agreement includes deposit payments to Lilium for delivery of up to five Lilium Jets. Air-Dynamic SA will operate and manage these Lilium Jets for its customers in Switzerland and Italy, which will offer customers early access to the premium 'club configuration' Lilium Jet including the Lilium Pioneer Edition.

17:45 EDT Radian Group exec Ray sells 35,525 common shares - In a regulatory filing, Radian Group senior executive VP Eric Ray disclosed the sale of 35,525 common shares of the company on May 19 at a price of $25.6691 per share.

17:41 EDT Icosavax announces positive topline interim phase 1 results for IVX-A12 - Icosavax "announced positive topline interim results from its Phase 1 clinical trial of IVX-A12 against respiratory syncytial virus and human metapneumovirus in older adults. IVX-A12 is comprised of IVX-121, Icosavax's RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax's hMPV prefusion F protein VLP vaccine candidate." "IVX-A12 is a potential first-in-class combination vaccine candidate designed to address an unmet medical need in older adults, and we believe these interim data for hMPV in an older adult population also break new ground in the field. As has been seen previously with prefusion F antigen approaches for RSV, we expect that a combination vaccine displaying prefusion F antigens for both hMPV and RSV, on our VLP technology, may translate into significant protection against two leading causes of pneumonia. We plan to expeditiously proceed towards a Phase 2 trial for IVX-A12 in mid-2023 in older adults as we pursue our goal of developing a broader viral respiratory vaccine," said Adam Simpson, CEO.

17:33 EDT Brown & Brown to acquire Kentro, terms undisclosed - Brown & Brown announced that Brown & Brown has entered into an agreement to acquire Kentro. The transaction is expected to close in the fourth quarter, subject to certain closing conditions, including the receipt of required regulatory approvals. Kentro is an insurance industry group headquartered in London, managing over GBP 500M of gross written premium. The collective Kentro team is composed of more than 350 insurance professionals operating from offices in the U.K., U.S., Europe, Asia and Dubai. From its founding in 2008, the Kentro companies, Nexus, Xenia, Millstream, Capstone Brokers and Spectrum Risk Management, have focused on product specialization and underwriting discipline. Currently, Nexus underwrites across a diversified portfolio of 20 risk classes, including trade credit, financial lines and aviation, through a network of over 800 retail broker partners in nine countries. The Nexus operating platform is purpose-built to maximize growth and underwriting performance. Xenia is one of the largest retail trade credit brokers in the U.K., with over 1,500 policyholders ranging from large corporates to SME customers. Millstream operates as a specialty travel and personal accident provider; Capstone Brokers provides access to the Asian marketplace for complex financial lines and digital asset risks; and Spectrum Risk Management offers intermediary, agency and advisory services in the MENA regions and Asia. The Kentro Group and its individual business entities will continue to trade and operate as they have historically, with the same leadership team, brand and market focus.

17:26 EDT Bar Harbor Bankshares announces 756,000 shares repurchase program - Bar Harbor Bankshares announced that its Board of Directors authorized the repurchase of up to 756,000 shares of its outstanding common stock, representing approximately 5% of its shares as of April 30 under a share repurchase plan. The Plan is authorized to last no longer than 12 months. Share repurchases, if any, will be made from time to time in the open market, through block trades, or otherwise, in private negotiated transactions.

17:24 EDT Saia to open new LTL freight terminal in Muncie, Indiana - Saia Inc "announced the opening of its new Saia LTL Freight terminal in Muncie, Indiana. The facility is another investment in our service for customers in central Indiana and further enhances our statewide coverage."

17:15 EDT Akebia regains compliance with Nasdaq minimum bid price requirement - Akebia Therapeutics announced that it has received a formal notice from The Nasdaq Stock Market stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Akebia is in compliance with all applicable listing standards. On May 9, 2023, Akebia was notified by Nasdaq that Akebia had not regained compliance with the big price requirement during the compliance period and Akebia's securities were subject to delisting. Akebia filed an appeal and was granted a hearing before the Nasdaq Hearings Panel. Since Akebia has regained compliance, the hearing has been canceled. Akebia's stock will continue to be listed and traded on The Nasdaq Capital Market.

17:07 EDT General Dynamics awarded $736.16M Navy contract modification - General Dynamics was awarded a $736.16M modification to previously-awarded contrac to exercise the option for the detail design and construction of T-AO 213. Work is expected to be completed by March 2028. FY23 shipbuilding and conversion funds in the amount of $736.16M will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:00 EDT Signal Hill Acquisition announces liquidation - Signal Hill Acquisition announced that, due to its anticipated inability to consummate an initial business combination within the time period required by its Second Amended and Restated Certificate of Incorporation, the Company intends to dissolve and liquidate in accordance with the provisions of its Second Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.43.

16:59 EDT Equus subsidiary, Morgan E&P, buys 4,747 net acres in the Bakken - Equus Total Return announced the closing of a Purchase and Sale Agreement between Morgan E&P, LLC, a wholly-owned subsidiary of Equus, and Pro Energy I, LLC. Pursuant to the PSA, Morgan has acquired 4,747.52 net acres, in the Bakken/Three Forks formation in the Williston Basin of North Dakota. In addition to other terms and conditions, including a payment of $500,000, Morgan is required to drill and complete a minimum of six wells within 18 months of receiving the first drilling permits. The average cost of drilling a new horizontal well is approximately $8.0 million.

16:51 EDT Tegna announces $300M ASR agreement with JPMorgan Chase Bank - TEGNA (TGNA) announced a $300M accelerated share repurchase, or ASR. TEGNA will enter into a $300M ASR agreement with JPMorgan (JPM) Chase Bank, which is expected to be completed by the end of the Q3. The ASR will be funded through cash on hand, which stood at $683 million at the end of the Q1.

16:47 EDT Topgolf Callaway exec buys $113.6K in common stock - In a regulatory filing, Topgolf Callaway disclosed that its EVP Rebecca Fine bought 7K shares of common stock on May 22nd a total transaction size of $113.6K. Shares of Topgolf Callaway are up 2.7% afterhours at $16.90.

16:38 EDT General Motors CFO buys $1.01M in common stock - In a regulatory filing, General Motors disclosed that its CFO Paul Jacobson bought 31K shares of common stock on May 19th in a total transaction size of $1.01M.

16:34 EDT Flywire director Harris sells 1M common shares - In a regulatory filing, Flywire director Matthew Harris disclosed the sale of 1M voting common shares of the company on May 18 at a price of $30.60 per share.

16:33 EDT US Foods chief commercial officer Iacobucci to leave company - US Foods Holding announced key changes to its Executive Leadership Team effective today. Andrew Iacobucci, Senior Executive Vice President, Field Operations and Chief Commercial Officer is leaving US Foods to accept a CEO role outside the company. Iacobucci served as the company's Interim CEO in 2022 prior to Dave Flitman filling the permanent CEO position in January 2023. With Iacobucci's departure, the company has taken the opportunity to flatten its Executive Leadership Team structure and has named Jim Sturgell, Executive Vice President, Chief Commercial Officer responsible for Local Sales, Commercial Excellence, and Merchandising/Marketing and Randy Taylor, Executive Vice President, Field Operations with P&L responsibility for the company's Broadline business and Stock Yards. Both will report to Flitman as part of his ELT. "We thank Andrew for his leadership, particularly for his service as Interim CEO last year, and wish him much success," said Flitman. "We have a strong bench of talent here at US Foods. I am confident that Jim and Randy will bring their years of experience, strong track records and leadership skills to their new appointments and play key roles in driving continued execution against our long-range plan."

16:31 EDT AST SpaceMobile set to join Russell 2000, Russell 3000 Indexes - AST SpaceMobile is set to join the small-cap Russell 2000 and broad-market Russell 3000 indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 28, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

16:31 EDT F45 Training receives NYSE notice of non-compliance - F45 Training Holdings announced that it received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's Common Stock was less than $1.00 over a consecutive 30 trading-day period. The notice has no immediate effect on the listing of the company's stock on the NYSE. The company intends to respond to the NYSE within ten business days of receipt of the notice affirming its intent to cure the deficiency. Pursuant to the NYSE's rules, the company has a six-month period following receipt of the notice to regain compliance with the NYSE's minimum share price requirement.

16:25 EDT CSX reaches tentative sick leave agreement with SMART-TD CSRA - CSX announced that it has reached a tentative agreement with the Sheet Metal, Air, Rail and Transportation Workers-Transportation Division CSRA, or SMART-TD CSRA, to provide paid sick leave benefits. SMART-TD CSRA represents trainmen, conductors and yardmen on territories of the former A&WP, WSSB, L&N, NC&STL and SCL railroads. The SMART-TD CSRA agreement, which is pending ratification by union members, marks the 10th such agreement CSX has reached with its union-represented employees since February. A majority of the company's unionized workers now have paid sick leave benefits.

16:23 EDT GeneDx receives noncompliance notice from Nasdaq - GeneDx announced that it had received a letter from Nasdaq stating that, because the company's Class A common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450, and that the matter is now closed.

16:18 EDT Bruker director Kastner sells 11,146 common shares - In a regulatory filing, Bruker director Marc Kastner disclosed the sale of 11,146 common shares of the company on May 19 at a price of $75.22 per share.

16:17 EDT Lamb Weston names Sukshma Rajagopalan chief information and digital officer - Lamb Weston announced that Sukshma Rajagopalan will join the company as Chief Information and Digital Officer, effective June 26, 2023. She will lead the development and execution of the company's digital strategy, reporting to Tom Werner, President and CEO. Rajagopalan has more than 25 years of experience leading digital and IT teams, most recently as Senior Vice President and Chief Digital Officer at Avantor, where she led all aspects of the company's global enterprise digital roadmap, including finance, supply chain and commercial solutions as well as data and analytics including automation and AI. Prior to joining Avantor, she held IT and digital leadership roles at PepsiCo and Kraft Foods. "I'm looking forward to Sukshma joining our executive team in this new role," said Tom Werner. "Her breadth of experience in the digital space and her deep knowledge of the food industry will help us to unlock even more value in our digital and technology strategies," said Werner.

16:10 EDT Zoom Video reports 3,580 customers contributing more than $100,000 in Q1 - Reports Q1 online average monthly churn of 3.1%. The percentage of total Online MRR from Online customers with a continual term of service of at least 16 months was 72.0%, up 700 bps year over year. Reports approximately 215,900 Enterprise customers, up 9% from the same quarter last fiscal year.

16:08 EDT Transcat sees FY24 income tax rate 21%-23% - Rudow concluded, "We are proud of our dedicated team, which has consistently delivered exceptional results through various economic cycles as can be seen over the past 10 plus years of profitable growth. As we think ahead into fiscal 2024, despite macroeconomic uncertainty that looms over the business world, we expect another year of growth and margin expansion across our Service channels. Our business continues to benefit from a predominately life science-oriented market, driven by high levels of regulation and recurring revenue streams, along with a growing Rentals business that tends to perform well throughout various economic cycles including more challenged economic environments. In the year ahead, we expect organic Service revenue growth in the high single-digits and gross margin improvement to continue. We are investing in our high-growth NEXA business as well as new client-based labs, which will support additional organic revenue growth and margin expansion in the second half of the year but will temporarily weigh on year-over-year gross margin expansion in the first quarter of FY24. Accretive acquisitions that strengthen our fundamental value proposition will be a key component of our go-forward strategy. Our robust and diverse acquisition pipeline enables opportunities for Transcat to expand addressable markets and increase our capabilities like we did with NEXA and the pipettes business. Transcat has generated consistent margin improvement over the past several years and we believe the improvement will continue. Automation of our calibration processes and overall process improvement will be key enablers to future margin expansion. We anticipate demonstrating more selling, general and administrative expense leverage in the second half of fiscal 2024. We believe the Service segment has substantial runway ahead for growth, both organically and through acquisition. We have a long history of generating sustainable value for our shareholders and providing a dynamic, rewarding workplace for our team."

16:06 EDT Blueprint Medicines announces FDA approval of AYVAKIT from treatment of SM - Blueprint Medicines announced that the FDA has approved AYVAKIT, or avapritinib, for the treatment of adults with indolent systemic mastocytosis, or SM. All U.S. patients with ISM now have access to the first and only approved medicine designed to treat their disease. Systemic mastocytosis, or SM, is a rare hematologic disorder that can lead to a range of debilitating symptoms across multiple organ systems and a significant impact on patients' quality of life. ISM represents the vast majority of SM cases, and AYVAKIT is now available for adults with ISM at the recommended dose of 25 mg once daily. AYVAKIT was designed to potently and selectively inhibit KIT D816V, the primary underlying driver of the disease. AYVAKIT has been FDA approved for the treatment of advanced SM since June 2021. The approval of AYVAKIT in ISM is based on data from the double-blind, placebo-controlled PIONEER trial - the largest study ever conducted for this disease - in which patients received AYVAKIT 25 mg once daily plus best supportive care or placebo plus best supportive care. AYVAKIT demonstrated significant improvements versus placebo in the primary and all key secondary endpoints, including overall symptoms and measures of mast cell burden. AYVAKIT was well-tolerated with a favorable safety profile compared to placebo, and most adverse reactions were mild to moderate in severity. The most common adverse reactions for AYVAKIT (greater than or equal to10 percent) were eye edema, dizziness, peripheral edema and flushing. Serious adverse reactions and discontinuations due to adverse reactions occurred in less than 1% of patients.

16:03 EDT Atea Pharmaceuticals up 37% after buyout offer from Tang Capital

15:21 EDT Blueprint Medicines' Ayvakit gets expanded approval for ISM - Blueprint Medicines' Ayvakit received approval for indications that are expanded to include indolent systemic mastocytosis, or ISM, according to updated prescribing information posted to the site of the FDA. Reference Link

14:37 EDT JPMorgan's Dimon says board will decide post-CCAR on dividend - JPMorgan CEO Jamie Dimon said the board decides on the dividend and will make a decision regarding any dividend increase following the results of the Fed's CCAR test. Dimon is speaking during JPMorgan's investor day meeting.

13:19 EDT Aerovate Therapeutics present nonclinical pharmacokinetic data on AV-101 - Aerovate Therapeutics presents results from a series of studies in nonclinical species assessing the pharmacokinetics of different formulations of imatinib at the American Thoracic Society 2023 International Conference in Washington, D.C. Aerovate is developing inhaled imatinib as AV-101 for the treatment of pulmonary arterial hypertension. While oral imatinib has previously demonstrated clinically significant efficacy in PAH patients in the global Phase 3 IMPRES trial conducted by Novartis, the oral formulation was poorly tolerated due to adverse events. The studies investigated the pharmacokinetics of imatinib in nonclinical models, including mice, rats, and cynomolgus monkeys, following delivery of imatinib formulations directly into the lungs compared to other routes of administration. Data showed that lung exposure in mice and rats following dry powder inhaled delivery was substantially higher versus oral delivery, and the dry powder formulation of imatinib enhanced lung exposure in rats over direct delivery of suspension or solution, and improved lung exposure versus oral or intravenous delivery. Repeat dosing of dry powder aerosol to rats and monkeys also suggested concentrations were maintained in the lungs after 24 hours. Measurements of the active imatinib metabolite, N-desmethyl imatinib, showed no apparent contribution to imatinib metabolism arising from the lungs. Plasma time course profiles of imatinib after direct dry powder or suspension dosing in rats were indicative of dissolution-controlled absorption. These nonclinical results suggest that the AV-101 formulation and inhaled delivery of imatinib can enhance lung exposure at a lower dose versus oral administration. A previous Phase 1 study of AV-101 in healthy volunteers demonstrated significantly lower systemic exposure compared to oral imatinib. AV-101 was generally well-tolerated, suggesting that lower systemic exposure can potentially decrease the side-effects associated with oral imatinib for the treatment of PAH. Aerovate continues to enroll IMPAHCT, a multi-national, placebo-controlled Phase 2b/Phase 3 trial that is evaluating the safety and efficacy of AV-101 in adults with PAH. Aerovate expects to report topline data from the Phase 2b portion of the trial in the second quarter of 2024.

13:04 EDT Kiromic: AI integrated with each stage of Kiromic therapy production lifecycle - In investor presentation slides, Kiromic said its Diamond Donor AI uses demographics, cytometry, and sequence data to identify the best GDT cell donors, and that Diamond Clinical AI models can continually improve the AI model to maximize efficiency. Looking ahead, Kiromic sees the beginning of the first in-human trial activation for Deltacel in Q2, with data results from the first patient in the trial by the end of Q4. It sees the initiation of clinical trials expansion cohort in 2H24, with the submission of new INDs for Procel and Isocel in 1H25.

12:26 EDT Coinbase launching 'Crypto: Moving America Forward' ad campaign - Coinbase is launching Crypto: Moving America Forward, "a national campaign to explain crypto's critical role as an underlying technology that will update the global financial system. With China embracing and advancing the use of technology, including digital assets, to project power, Crypto: Moving America Forward will also make clear that US global economic leadership and national security are at risk if the US cedes its role in building technology that will be central to the world's financial infrastructure." Coinbase's campaign begins with a series of four ads featuring CEO Brian Armstrong, the company said in a blog post, stating that "These ads will air on popular Sunday shows, with a new chapter premiering each weekend. Together, they will explain why crypto matters and what is at stake for the United States." Reference Link

12:14 EDT JPMorgan sees invesment banking fees down 15% in Q2 - Also sees markets revenue down about 15% in Q2. Comments taken from JPMorgan's Investor Day event.

12:09 EDT NWTN announces plans for strategic partnership with CMEC Middle East Fze - NWTN and CMEC Middle East Fze, a subsidiary of China Machinery Engineering Corporation, announced plans for a strategic partnership, which has been memorized in a non-binding memorandum of understanding on May 18, 2023. This proposed partnership seeks to capitalize on the combined expertise, resources, and networks of NWTN and CMEC ME, aiming to enhance market presence, foster innovation, and deliver exceptional value to customers, the companies said.

12:01 EDT Telesis Bio announces first commercial shipment of BioXp select DNA cloning kit - Telesis Bio announced the first commercial shipment of its BioXp Select DNA Cloning kit. "The principle of RNAimmune's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. Our research focuses on optimizing the mRNA molecule for delivery, function, and other key characteristics and requires rapid analysis and iteration. The BioXp System is a key part of our process, enabling us to reduce timelines, eliminate manual steps, and more broadly test and iterate. We expect the new Select DNA Cloning kit to be of great value in our candidate optimization and screening workflows for mRNA vaccines," said Dong Shen, M.D., Ph.D., Founder and President of RNAimmune.

12:00 EDT Quad/Graphics falls -6.9% - Quad/Graphics is down -6.9%, or -28c to $3.71.

12:00 EDT Ouster rises 16.6% - Ouster is up 16.6%, or 85c to $5.96.

12:00 EDT Greenhill & Co. rises 117.0% - Greenhill & Co. is up 117.0%, or $7.93 to $14.71.

11:15 EDT Pfizer up 3% after report on weight loss drug study results - Shares of Pfizer are up $1.22, or 3%, to $37.99 in Monday morning trading.

11:03 EDT Bristol-Myers announces results from Phase 2 study of BMS-986278 - Bristol Myers Squibb announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis. These data, presented today at the American Thoracic Society 2023 International Conference, showed twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity by 62% compared to placebo. Pulmonary fibrosis is a devastating, life-threatening illness, with daily symptoms including coughing, labored breathing and extreme fatigue. "The in-house development of BMS-986278 and progress of our pulmonary fibrosis program are a direct result of our industry-leading drug discovery and development capabilities, underscoring our expertise in disease biology and medicinal chemistry. These Phase 2 data give us the confidence to initiate our global Phase 3 clinical trial program where we will continue exploring BMS-986278 as a potentially new and meaningful therapeutic option for people with pulmonary fibrosis," said Samit Hirawat, MD, chief medical officer, Bristol Myers Squibb.

11:01 EDT Precipio leverages HemeScreen technology to monitor CML patient - Precipio leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression. While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio's clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician. Changes in isoform expression may happen over time during the course of treatment. The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.

10:35 EDT WhatsApp introduces 'Edit' feature for sent messages - In a company blog post, WhatsApp said, "For the moments when you make a mistake, or simply change your mind, you can now edit your sent messages. From correcting a simple misspelling to adding extra context to a message, we're excited to bring you more control over your chats. All you need to do is long-press on a sent message and choose 'Edit' from the menu for up to fifteen minutes after. Edited messages will display 'edited' alongside them, so those you're messaging are aware of the correction without showing edit history. As with all personal messages, media and calls, your messages and the edits you make are protected by end-to-end encryption. This feature has started rolling out to users globally and will be available to everyone in the coming weeks."

10:11 EDT SQM announces long-term lithium supply agreement with Ford - SQM (SQM) and Ford (F) announced a long-term strategic agreement to secure the supply of lithium products for production of electric vehicles. The agreement between Ford and SQM will ensure the supply of battery-grade lithium carbonate and lithium hydroxide, essential components to manufacture high-performance electric vehicle batteries. The origin of SQM's lithium should help Ford vehicles to qualify for the Inflation Reduction Act consumer tax credit and will help support its plans to produce electric vehicles and expand its presence in the global electric mobility markets. Carlos Diaz, Executive Vice President Lithium of SQM, said: "We are pleased to announce this strategic agreement and value Ford's trust in SQM's ability to deliver battery-grade lithium products sustainably produced in Chile."

10:06 EDT Ford sees Ford Blue EBIT margin in low double digits by 2026 - Comments taken from the Delivering Ford+ Capital Markets Day.

10:00 EDT Daily S&P Biotech Bear 3x Shares falls -5.0% - Daily S&P Biotech Bear 3x Shares is down -5.0%, or -68c to $12.88.

10:00 EDT TrueBlue rises 9.7% - TrueBlue is up 9.7%, or $1.56 to $17.60.

10:00 EDT Greenhill & Co. rises 116.4% - Greenhill & Co. is up 116.4%, or $7.89 to $14.67.

09:47 EDT Revolve Group falls -4.7% - Revolve Group is down -4.7%, or -77c to $15.78.

09:47 EDT United States Natural Gas Fund falls -5.0% - United States Natural Gas Fund is down -5.0%, or -37c to $7.09.

09:47 EDT Global Indemnity rises 8.3% - Global Indemnity is up 8.3%, or $2.08 to $27.29.

09:41 EDT MNK Stock trading resumes

09:36 EDT MNK Stock trading halted, volatility trading pause

09:32 EDT Diana Shipping announces time charter contract for m/v Selina - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Cargill International S.A., Geneva, for one of its Panamax dry bulk vessels, the m/v Selina. The gross charter rate is US$12,000 per day, minus a 4.75% commission paid to third parties, for a period until minimum September 15, 2024 up to maximum November 15, 2024. The charter commenced on May 20, 2023. The "Selina" is a 75,700 dwt Panamax dry bulk vessel built in 2010. The employment of "Selina" is anticipated to generate approximately US$5.71 million of gross revenue for the minimum scheduled period of the time charter.

09:32 EDT FORME, Aethos partner for training technology in hotels - Aethos announce sits brand partnership with FORME. As part of the partnership, Aethos will be the first hotel brand in Portugal, Spain and Italy to feature FORME's revolutionary products in all its hotels and member clubs. Aethos' newest refuge in the Italian Alps, Aethos Monterosa, which is opening June 1st, will be the first destination to feature the FORME Studio in its Gym and Aethos Suites. The workout mirror with a 4K touch screen that makes it feel like the trainer is right there with you, will complement the extensive wellbeing programming that the hotel offers; from an expansive indoor / outdoor spa, yoga, Pilates and boxing classes, to an indoor climbing hall.

09:23 EDT Enzo Biochem: Preliminary voting results show approval of Asset Sale Proposal - Enzo Biochem announced that the preliminary voting results from the Inspector of Election at today's Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo's outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the operating assets and assignment of certain liabilities of Enzo's Clinical Labs division.

09:17 EDT Spok to join Russell 3000 Index - Spok is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.

09:16 EDT FG Financial unit in pact with ThinkMarkets, no terms - FG Financial Group announced that its merchant banking platform partner FG Acquisition has entered into a business combination agreement with ThinkMarkets, one of the fastest growing online and leveraged trading multi-asset brokerages globally. ThinkMarkets provides its customers with access to over 10,000 CFDs, including but not limited to, equities, currencies, precious metals, indices, commodities, ETFs and other trading products. The business combination would result in ThinkMarkets launching as a public company listed on the Toronto Stock Exchange. FG Financial Group is a reinsurance and asset management holding company focused on collateralized and loss capped reinsurance and merchant banking that allocates capital in partnership with Fundamental Global , a private partnership led by Kyle Cerminara and Joe Moglia, as well as other strategic investors.

09:14 EDT Global Industrial acquires Indoff for $69.2M in cash - Global Industrial Company announced that it has acquired 100% of the issued and outstanding equity interests of Indoff for approximately $69.2 million in cash. The acquisition was funded from the Company's existing credit facility and cash on hand. Indoff generated revenue of approximately $180 million in 2022. Indoff will continue to operate under its current brand and leadership team as a wholly-owned subsidiary of Global Industrial Company.

09:14 EDT Fifth Third acquires Rize Money, terms undisclosed - Fifth Third announced the acquisition of Rize Money, an embedded payments platform that provides payment infrastructure and risk management capabilities to fintechs and other technology companies that want to offer innovative financial products through a single application programming interface. Embedded payments is a core component of Fifth Third's Treasury Management business, supporting clients who value scale, risk sophistication and full range of payment types. The business is growing at double digits and the annual revenue is projected to eclipse $130 million this year, complementing the existing embedded payments and Treasury Management businesses. Founded in 2014 by Justin Howell, Rize Money, Inc. is headquartered in Arlington, Virginia. The acquisition was made by an indirect wholly owned subsidiary of Fifth Third and financial terms of the transaction were not disclosed.

09:13 EDT XBiotech announces FDA authorized Phase II study for Natrunix - XBiotech reports that the FDA's Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix as a treatment for Rheumatoid Arthritis. The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared to placebo in subjects already receiving stable but inadequate treatment with methotrexate. A total of 210 patients will be randomly distributed in equal numbers into three groups: including two different Natrunix dosages and a placebo group. Change in disease severity will be assessed at multiple time points according to the American College of Rheumatology grading scale. Subjects will also be assessed for reduction in pain, number of tender or swollen joints as well as overall disease activity. The study concludes after subjects have received 12 cycles of therapy and follow-up.

09:11 EDT Nayax appoints Aharon as COO, Tepper as CCO - Nayax announced the appointments of Yaron Aharon as Chief Operating Officer, COO, and Oren Tepper as Chief Commercial Officer, CCO. As Chief Operating Officer, which is a new role at Nayax, Yaron will report to Chief Executive Officer, Yair Nechmad and will be responsible for coordinating and managing operations as well as procurement and information systems across Nayax's global businesses. He previously served as Chief Operating Officer at Orpak Systems, part of the Gilbarco Veeder-Root Group. Oren will be the first to serve as Chief Commercial Officer at Nayax and will be responsible for the company's global sales initiatives. His role is to focus on the company's diverse and global customer base, while emphasizing their multi-year plans for growth.

09:09 EDT JPMorgan expects Basel III proposal 'any day now'

09:08 EDT JPMorgan sees about half of First Republic integration costs this year

09:08 EDT JPMorgan: First Republic now embedded in guidance

09:07 EDT Meltwater announces AI-powered product innovations aross solutions - Meltwater announces new AI-powered product innovations across multiple solutions that allow customers to surface insights, boost efficiency, and generate content. The company said, "New product enhancements powered by Meltwater's AI engine: AI Writing Assistant - Empowering customers to work more efficiently and overcome writer's block, leveraging the latest advancements in generative AI. Powered by OpenAI's GPT model, this intuitive tool boosts productivity and creativity, providing users with an effortless way to craft highly engaging content, integrated seamlessly into their publishing workflow. Discovery AI-Based Insight Assistant - Leveraging advanced artificial intelligence algorithms to automatically surface impactful consumer and market insights. By highlighting changes, shifts, and trends in online conversations that teams may have otherwise missed, the assistant allows them to stay ahead of the curve and make informed business decisions, solving for information overload with automated, actionable insights. Video Analysis - Enabling users to capture insights from video content on social platforms through advanced computer vision which identifies logos, celebrities, scenes and objects. This allows customers to gain a more comprehensive understanding of their online brand and tackle everything from crisis management to content ideation."

09:06 EDT Lucy Scientific's Amanita line available for purchase through retail channels - Lucy Scientific Discovery announces Mindful, an innovative functional Amanita based product line is now available through multiple retail channels. "We are thrilled that Mindful will be available to consumers, and our excited about the revenue potential," stated Chris McElvany, CEO of Lucy Scientific Discovery Inc. "Our goal is to offer Mindful to consumers directly through our platform and a variety of 3rd party platforms and traditional retail channels. Mindful by Lucy is a testament to our dedication to providing exceptional quality and a mindful approach to wellness."

09:04 EDT Keros Therapeutics presents preclinical, clinical data from KER-012 program - Keros Therapeutics announced that it presented additional biomarker data from its completed Phase 1 clinical trial of KER-012 in healthy post-menopausal women at the American Thoracic Society, ATS, 2023 International Conference, held from May 19 through May 24, 2023. In addition, Keros presented preclinical data showing the potential of a research form of KER-012 to improve left ventricular function in a mouse model of left ventricular pressure overload, as well as preclinical data evaluating transforming growth factor-beta signaling in two major cell types involved in the dysregulated vascular remodeling in pulmonary arterial hypertension, and KER-012's effect on this ligand-induced signaling. "We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year. The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases. From our completed Phase 1 clinical trial of KER-012 in healthy post-menopausal women, we presented new data with observed sustained changes in serum biomarkers of cardiac dysfunction, inflammation and fibrosis," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. "We believe these data support the potential of KER-012 to treat fibrosis and inflammation in patients with PAH and in patients with cardiovascular disease."

09:03 EDT LPL Financial supports launch of Bridgewright Wealth Partners - LPL Financial LLC announced that financial advisors Bruce Pienton and Scott O'Mara CFP, CRPS, AAMS, have launched a new independent practice, Bridgewright Wealth Partners, through affiliation with LPL Strategic Wealth Services, the firm's modern breakaway solution for advisors seeking to gain more control over their business. The advisors reported having served approximately $240 million in advisory and brokerage assets, and they join LPL from Wells Fargo Advisors. Based in Grand Rapids, Pienton and O'Mara are Michigan natives with a collective 60+ years of industry experience, both who are entrepreneurs at heart. They each bring a unique perspective to their work, guiding families and business owners through the challenges of growing, maintaining and passing along wealth to heirs and causes they care about. They are joined by Bradley Day, longtime Director of Client Relations.

09:02 EDT GitLab launches GitLab 16 - GitLab announced the launch of GitLab 16, its latest major release. GitLab 16, includes new DevSecOps platform-wide capabilities available to customers now, and features GitLab plans to release throughout the year.

08:56 EDT Energy Vault signs agreement with Rept Battero to deliver lithium-ion batteries - Energy Vault has signed an agreement with Rept Battero Energy, a new energy solution provider backed by China's stainless steel and nickel giant Tsingshan Group, a provider of sustainable, grid-scale energy storage solutions, to supply 10GWh of high-energy capacity, high-density lithium-ion battery and other energy storage solutions. The deal will see Rept Battero initially deliver 280Ah batteries, followed by the company's next-gen Wending Battery. Initial deliveries are expected to start in Q3 2023.

08:50 EDT Envela set to rejoin Russell 3000 Index - Envela is set to rejoin the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.

08:49 EDT OSI Systems awarded an order of $10M for mobile cargo - OSI Systems announced that its Security division was awarded an order valued at approximately $10M to provide multiple units of the EagleM60 mobile high-energy cargo and vehicle inspection system and the Z Backscatter Van ZBV cargo and vehicle inspection system, including follow on maintenance, training and support. These inspection systems are expected to be deployed for international security requirements. OSI Systems' Chairman and CEO, Deepak Chopra, stated, "We are pleased to receive this award and look forward to supporting our vaalued customer's efforts to further enhance border and infrastructure security."

08:48 EDT GRI Bio provides upcoming milestones for pipelines - GRI Bio provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development. "We believe our leading NKT platform technology represents a compelling opportunity with the potential for significant value creation. Based on the data demonstrated to date, we have confidence in our ability to modulate inflammatory diseases earlier in the cascade to interrupt disease progression and provide benefit to patients. We continue to make solid progress in the advancement of our lead programs, GRI-0621 and GRI-0803, and are poised to reach a number of value-driving milestones in the near term," commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. "On the corporate front, we believe we have investment proceeds and access to additional investment to fund planned operations through 2024 and have bolstered the expertise of our team and Board of Directors. We are well prepared to rapidly propel the Company forward and are committed to providing much needed treatment options for inflammatory, fibrotic and autoimmune diseases." GRI-0621: Type 1 invariant NKT antagonist in development for the treatment of idiopathic pulmonary fibrosis. Expected Upcoming Milestones: H2 2023: Launch Phase 2a biomarker study; H1 2024: Report interim data from Phase 2a biomarker study; H2 2024: Report topline results from Phase 2a biomarker study. GRI-0803: Novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Expected Upcoming Milestones: Q1 2024: Complete IND-enabling studies; H1 2024: File IND; Q3 2024: Report Phase 1a SAD topline results; Q4 2024: Report Phase 1b MAD topline results

08:45 EDT MiNK Therapeutics presents clinical data on allogeneic iNKT cells - MiNK Therapeutics announced presentation of clinical data from its allo-iNKTs in COVID-19 associated Acute Respiratory Distress Syndrome at the American Thoracic Society International Conference in Washington D.C. Twenty patients with moderate to severe CARDS, including 4 patients on venovenous extracorporeal membrane oxygenation therapy, were treated with a single dose of agenT-797. Clinical results showed pronounced survival benefit and manageable safety profile including: Patients on VV ECMO treated with agenT-797 had 75% 90-day survival compared to 30% survival with in-hospital controls. agenT-797 was dosed to 1 billion cells with a tolerable safety profile, without oxygenation failure or other significant adverse events, including cytokine release syndrome. agenT-797 induced significant anti-inflammatory profile changes and improved lung function within 24 hours after administration in a patient on VV ECMO support. In the overall study, agenT-797 showed reduction in secondary infections, including an over 80% reduction in pneumonia at dose cohort 3 Bacterial pneumonia in one patient on VV ECMO cleared 12 days post-infusion of agenT-797.

08:45 EDT Inuvo appoints Lowenthal as President - Inuvo (INUV) announced the appointment of Barry Lowenthal, former CEO of Media Kitchen, as President. Lowenthal brings more than three decades of experience leading innovative marketing agencies, while delivering growth and enhanced value for stockholders. Most recently, he served as CEO of Media Kitchen, an award-winning full-service communications planning and buying agency, which is a member of the Stagwell Media Network (STGW)

08:43 EDT Capstone secures order for 800kW Biogas microturbine energy solution in Spain - Capstone Green Energy announced that Micropower Europe S.L., its distributor in Spain and Portugal, has secured an order for a C800 Signature Series with a Micropower biogas treatment unit and four heat recovery modules. The unit will be operated at a landfill to produce electricity for waste management and recycling operations. It is expected to be commissioned in October 2023. "The versatility of Capstone microturbines is evident in every new order we receive, but our customers are choosing Capstone for many of the same reasons: fuel flexibility along with high reliability on a range of fuels, low maintenance requirements, and of course, lower carbon emissions. Our customers are looking for cleaner, greener ways to approach their operations, and Capstone is here to support them in reaching their goals," said Capstone Green Energy President and Chief Executive Officer Darren Jamison.

08:42 EDT Cellebrite to deploy suite of digital intelligence software into Latin America - Cellebrite DI announced its suite of digital intelligence software solutions, which includes the first and largest deployment of data and insights from cryptocurrency transactions in the Latin American public sector, will now be deployed in a major Latin American country, expanding the nation's four federal forces' digital forensic solutions. This significant agreement enables the police force to: Deploy Cellebrite's industry-leading Collect and Review solutions with UFED, Premium Enterprise and Premium as a Service, and Physical Analyzer; Benefit from Pathfinder, Cellebrite's sophisticated AI-based solution for rapidly analyzing enormous volumes of digital evidence across multiple devices; Leverage both crypto data and insights from Cellebrite and the cryptocurrency platform to identify, assess and accelerate investigations involving cryptocurrencies.

08:41 EDT Microbot says achieved 100% success rate for LIBERTY in preclinical study - Microbot Medical announced an extended joint pre- clinical animal study held at a leading European-based research lab. A team of six leading European interventional radiologists utilized the system and performed a total of 48 catheterizations to pre-determined vascular targets including distal branches of hepatic, gastric, splenic, mesenteric, renal, and hypogastric arteries, with a 100% success rate of reaching the intended target. Based on real-time user feedback, the interventional radiologists found the system intuitive, easy to set up and use, and were impressed with the ability to control procedures remotely via the LIBERTY Robotic System's remote controller. The Company plans on performing pre-clinical studies in the U.S. and other target markets, as well as first-in-human case in markets outside the U.S. in preparation for the continued progression toward commercialization of the LIBERTY Surgical Robotic System. The 48 successful catheterizations are part of the Company's recent announcement regarding surpassing 100th catheterization during multiple pre-clinical studies, with a 95% success rate of reaching pre-determined vascular targets.

08:40 EDT Ford sees decline in gasoline-fueled vehicles after 2025

08:39 EDT KULR Technology wins additional order from U.S. military - KULR Technology Group received a development contract from a branch within the United States Armed Forces to develop high-energy battery packs for uninterruptible power supplies to mobile command centers.

08:38 EDT One Stop Systems appoints Knowles as president, CEO - One Stop Systems announced that Michael Knowles has been appointed as its new President and CEO, effective June 5, 2023. Knowles has held executive leadership positions at several defense contractors, including Cubic Corporation, Rockwell Collins, Lockheed Martin, and Curtiss Wright Defense Solutions. Over his career he has effectively developed and launched market-changing technologies and products in both defense and commercial markets. Consistent with previous announcements, David Raun's last day as the company's President and CEO will be June 5, 2023, the same day on which Knowles will begin serving in such roles.

08:36 EDT Coherus Biosciences announces U.S. launch of UDENYCA autoinjector - Coherus BioSciences announced that the single-dose, prefilled autoinjector presentation of UDENYCA is now available for commercial sale in the United States. UDENYCA is a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.1 UDENYCA AI's streamlined design offers a simple option for in-office and at-home settings of care that administers pegfilgrastim in less than 10 seconds. "Patients have indicated in market research that quick administration, ease of use, and a sense of control and independence were the features and benefits of the autoinjector most important in their decision-making when choosing an at-home administration option. With UDENYCA AI, providers now have a new option that offers their patients where and how to receive their therapy, and health plans have a new option to increase access for patients," said Paul Reider, Chief Commercial Officer of Coherus. "Our goal is to be the only pegfilgrastim product offering value across three differentiated presentations, fully meeting market needs and creating a durable franchise positioned to maximize market share growth. UDENYCA(R) AI represents substantial progress in that direction, and UDENYCA(R) will become the only pegfilgrastim product with three presentation options with the launch of our proprietary on-body injector later this year, if approved."

08:35 EDT Bit Brother Limited receives non-compliance notification letter from Nasdaq - Bit Brother received a notification letter from Nasdaq notifying the company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the company therefore no longer meets the minimum bid price requirements in Nasdaq Listing Rules. The notification has no immediate effect on the listing of the company's ordinary shares on Nasdaq. The company has until November 13 to regain compliance. If the company does not regain compliance during such 180-day period, the company may be eligible for an additional 180 calendar days.

08:34 EDT Cricut board declares special cash dividend of $1.00 per share - Cricut announced that the Board of Directors, through its Audit Committee, has declared a special, one-time cash dividend of $1.00 per share to holders of the Company's Class A and Class B Common Stock. The dividend is payable on July 17, 2023, to stockholders of record at the close of business on July 3, 2023. The aggregate amount of the cash payment to be made in connection with this special dividend will be approximately $234 million. In addition, holders of restricted stock units that are unvested on the record date will be credited with a dividend equivalent based on the value of the per share dividend pursuant to the terms of the Company's equity incentive documents. The dividend equivalent will entitle such holders to receive additional shares upon vesting of the corresponding restricted stock units.

08:34 EDT Anixa Biosciences treats second patient in ovarian cancer CAR-T clinical trial - Anixa Biosciences announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. This study is a dose-escalation Phase 1 trial to evaluate safety and to determine the maximum tolerated dose of follicle stimulating hormone receptor T-cells and to preliminarily assess clinical activity. The study is being conducted at Moffitt Cancer Center. All patients being enrolled in the trial have disease that is progressing and have failed at least two, but often more, therapeutic interventions. This patient received the same dose of engineered T-cells as the first patient in the trial, and the next patient is expected to also receive the same dose. The successive three-patient cohort is expected to receive a higher dose of cells.

08:33 EDT ABVC BioPharma's Vitrargus Phase II study recieves ethical approve in Australia - ABVC BioPharma announced that the Vitrargus Phase II study at the Sydney Eye Hospital in New South Wales, Australia received ethical approval from the St. Vincent's Hospital Melbourne Human Research Ethics Committee on May 15, 2023. Early clinical studies indicate that Vitargus has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery, as well as significantly improve patient comfort and visual acuity during the surgical recovery period compared to currently available products. The objective of the Phase II study entitled "A Perspective Multi-Site Open-Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of ABV-1701 Ocular Endotamponade" is to demonstrate the safety and efficacy of Vitargus for the treatment of uncomplicated retinal detachment when compared to the commonly used SF6 Gas OE. The Phase II study will enroll at least forty patients and will be conducted in both Australia and Thailand. "We are extremely excited to receive the approval from St. Vincent's Hospital Melbourne Human Research Ethics Committee to conduct the Phase II study at Sydney Eye Hospital," said Dr. Howard Doong, Chief Executive Officer of the Company. "Sydney Eye Hospital will begin to recruit patients shortly under the direction of Professor Matthew Simunovic, Director, Chair Research Committee, joining the three other clinical sites in Thailand and Australia."

08:26 EDT PacWest sells $2.6B real estate construction loan portfolio to Kennedy-Wilson - In a regulatory filing 8-K filing, PacWest Bancorp stated: "Consistent with the previously announced strategy of PacWest Bancorp to pursue strategic assets sales and focus on our core community banking business, on May 19, 2023 our bank subsidiary, Pacific Western Bank, entered into a Loan Purchase and Sale Agreement with a wholly-owned subsidiary of Kennedy-Wilson Holdings, Inc. to sell to Kennedy Wilson a portfolio of 74 real estate construction loans with an approximate $2.6 billion aggregate principal balance currently outstanding. Kennedy Wilson or its designees will also assume all remaining future funding obligations under the acquired loans of approximately $2.7 billion. In addition, as part of the transaction, upon the Bank securing certain consents required under the underlying loan and related agreements, the Bank will also sell to Kennedy Wilson an additional six real estate construction loans with an aggregate principal balance of approximately $363 million. The sale of the loans is subject to customary closing conditions, including Kennedy Wilson's satisfactory completion of its due diligence review. In connection with the transaction, Kennedy Wilson will deposit a total of $20 million into a third-party escrow account that will be refundable back to Kennedy Wilson until it waives due diligence in accordance with the terms of the Agreement. The transaction is currently expected to close in multiple tranches during the second and early part of the third quarter of 2023."

08:22 EDT WNS Holdings announces Board approval of FY24 share repurchases - WNS announced that its Board of Directors has approved repurchases for fiscal 2024 under its existing share repurchase program. The company intends to begin the repurchases with immediate effect. "As disruption to our client's business models from technology advancements continues to accelerate, the opportunity for BPM partners like WNS to help deliver transformative solutions and business outcomes is increasing," said Keshav R. Murugesh, Group CEO, WNS. "Our strategic positioning in the marketplace and ability to 'co-create' custom solutions combining domain, technology, and talent makes WNS uniquely positioned to help clients create competitive advantage. This accelerated share repurchase program demonstrates the company's confidence in thelong-term health and resiliency of our business model, our differentiated capabilities, and our ability to execute. We expect to continue utilizing our strong balance sheet and balanced, disciplined approach to capital allocation to generate superior returns for our investors and long-term value for all our key stakeholders." Since 2015, WNS has repurchased 9.9 million shares of stock at an average price of $50.47.

08:21 EDT Panbela Therapeutics announces clinical trial with Moffitt Cancer Center - Panbela Therapeutics announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer. The initial goal of the Phase I trial will be to ascertain the maximum tolerated dose of eflornithine, while evaluating efficacy and then moving into a Phase II efficacy trial. We anticipate data from the Phase I trial by the end of this year with a look to start the Phase II trial at the end of the year or early 2024. "The relationship between polyamines and the immune system has been highlighted in peer-reviewed journals. This clinical trial with Moffitt seeks our first clinical proof of concept to evaluate the modulation of the immune system by polyamines in combination with standard of care cancer therapy," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "The STK11 mutant NSCLC population has historically had a poor response to checkpoint inhibitor therapy. If the trial is successful, it opens the door for combining polyamine targeted therapies, such as eflornithine and ivospemin, with checkpoint inhibitors in other tumor types where response rates have been poor, or even improve upon reasonable response rates. It would also open the possibility of exploring combinations of eflornithine and ivospemin with other immunotherapies, such as CAR-T therapy."

08:20 EDT BIO-key's PortalGuard selected by Wood County, OH - BIO-key International announced that Wood County, OH selected its PortalGuard IDaaS platform for improved security for desktop and application access and to meet regulatory and insurance compliance. PortalGuard was chosen through the County's competitive Request for Proposal vendor selection process. "County Governments continue to select BIO-key over competitive solutions because of our broad array of MFA capabilities and our cost-effectiveness," said Mark Cochran, President of BIO-key - PortalGuard. "With PortalGuard IDaaS, County IT teams can enable enhanced security capabilities while improving the login experience for on-premise and remote users. A core strength of PortalGuard is providing our customers flexibility in applying strong security to all elements of their environment while supporting a passwordless authentication model."

08:19 EDT Hanover Bancorp opens business banking center on Long Island - Hanover Bancorp expanded the Company's geographic footprint with the opening of its ninth location at 410 Motor Parkway, Hauppauge, New York. "This is an important milestone for us. We are thrilled to be a part of Suffolk County and look forward to serving the banking needs of so many vibrant businesses and residents through our commercial, municipal, and retail banking products and services," said Michael P. Puorro, Chairman & Chief Executive Officer. "The recent unrest and robust consolidation activity within our industry has created substantial voids in the quality and level of service available to many businesses, and we are eager to bring our banking solutions and highly personalized service to eastern Long Island. We are confident there is enormous growth potential in this vital and underserved market, and we will capitalize on these opportunities. As a financially strong and stable institution, we expect to create value for all our stakeholders by supporting our clients, becoming an integral part of this economic hub, and growing together with our clients."

08:18 EDT Nogin enters strategic alliance with RSM US - Nogin announces today that it has entered into a strategic alliance with RSM US. Through this strategic alliance, Nogin will help enable RSM to execute e-commerce initiatives with enhanced agility while simultaneously delivering enterprise grade solutions that scale. "I could not be more excited about working with RSM," said Shahriyar Rahmati, COO and CFO of Nogin. "With decades of personal, trusted relationships across RSM, a long history of witnessing its growth in the marketplace and firsthand knowledge of the firm's commitment to its clients, I am certain there is no firm better positioned to leverage our capabilities and assets alongside its own to the benefit of its clients. RSM uses technology to create value for its clients, which is the exact core mission of our business - creating clear win-win outcomes and bringing tangible, high ROI value to the marketplace. RSM's over 14,000 professionals in the U.S. and 57,000 professionals across 120 countries can accelerate our growth while enabling us to work closely together on collaborative innovation."

08:17 EDT aTyr Pharma presents new data on efzofitimod at the ATS - aTyr Pharma announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society, ATS, 2023 International Conference, which is scheduled to take place May 19 - 24 in Washington, DC. "Our presence at this year's ATS is an important opportunity for aTyr to feature the research we have generated that further support efzofitimod as a next generation immunomodulator with the potential to be a transformative, disease modifying therapy for interstitial lung disease (ILD)," said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. "We present new data showing that by binding to neuropilin-2, efzofitimod modulates immune responses through myeloid cells. By targeting multiple drivers of inflammation, efzofitimod provides a differentiated approach to resolving chronic inflammation. This major advancement in our mechanistic understanding of efzofitimod, in addition to new data that demonstrate a positive exposure-response for efzofitimod on multiple clinically relevant endpoints from a Phase 1b/2a study in pulmonary sarcoidosis patients, provide further evidence of clinical proof-of-concept."

08:15 EDT Enphase Energy expands IQ microinverter deployments in U.K. - Enphase Energy announced that installers of Enphase products in the United Kingdom have seen growing deployments of residential solar energy systems powered by the IQ7 family of microinverters. IQ7, IQ7+, and IQ7A Microinverters leverage Enphase's unique software-defined architecture and semiconductor integration for excellent reliability and economies of scale. Enphase microinverters are subjected to a rigorous reliability and quality testing regimen with more than one million hours of cumulative power-on testing to ensure exceptional performance under heat, high humidity, salty air, extreme cold, and harsh climate conditions. "All across Europe, we're witnessing extraordinary demand for advanced home energy solutions to increase energy independence and promote more sustainable lifestyles," said Marco Krapels, vice president of international sales at Enphase Energy. "Thanks to our regional manufacturing and experienced, robust network of installers in the United Kingdom, homeowners have more access to the industry's finest home energy technology to meet their needs."

08:15 EDT Jeffs' Brands says reduced time, costs launching products with ChatGPT - The company said, "Jeffs' Brands announced that it successfully reduced time and costs associated with launching new products on the Amazon Marketplace using ChatGPT and other artificial intelligence -based tools. By leveraging cutting-edge AI technology, Jeffs' Brands has harnessed the power of ChatGPT, an advanced language model, to streamline various aspects of its product development and customer support processes. This data-driven approach has enabled the Company to optimize efficiency, increase productivity, and enhance the overall customer experience. One key area where Jeffs' Brands has seen remarkable success is in market research. ChatGPT's ability to analyze customer preferences, identify emerging trends and analyze sentiment from customer reviews has provided the Company with invaluable insights. By leveraging this information, the Company has been able to make data-driven decisions to inform product development and marketing strategies, giving them a competitive edge in the Amazon Marketplace. In addition, Jeffs' Brands has optimized its product design process with the implementation of AI-powered chatbots. ChatGPT enables the Company to automate design and manufacturing related actions, reducing the need to use freelancers and remote vendors."

08:12 EDT PulteGroup appoints Kevin Henry Chief People Officer - PulteGroup announced that Kevin A. Henry has been appointed Executive Vice President and Chief People Officer reporting to the CEO. He will join the company on June 20. Henry brings more than 30 years of experience managing and developing talent and teams for major corporations. Most recently Kevin served as the Chief People Officer for BlueLinx Corporation, a leading wholesale distributor of residential and commercial building products with annual revenues of $4.5B. Previously, Henry was Chief People Officer at Extended Stay America, a hotel operator with more than 700 locations nationwide.

08:12 EDT Kratos, Clearbox Systems partner to develop satellite ground, space solutions - Kratos Defense & Security Solutions and Clearbox Systems have signed a collaboration agreement to co-develop and co-market solutions to advance the capabilities of software-defined satellite ground systems. As part of the agreement, Clearbox will integrate its flagship Foresight product to run seamlessly on Kratos' OpenSpace dynamic ground platform. Foresight provides a unified user interface across essential ground functions including equipment monitoring and control, spectrum monitoring and network management. Foresight can be deployed on physical, virtual or cloud infrastructure and, being web-based, can be accessed by users on any workstations connected on the network. "Our experience with Clearbox has been extremely productive," commented Stuart Daughtridge, SVP for Advanced Technologies at Kratos. "Their people and technology are first-class, and we are looking forward to putting our heads together on the cause of advancing virtual ground system technologies to enable systems that are as dynamic, flexible and agile as smart phones are today."

08:11 EDT Where Food Comes From named third-party verifier for Bee Friendly program - Where Food Comes From announced it has been selected as the exclusive third-party verifier for the Bee Friendly Farming Certification program. More than 450 farms currently participate in the program under the second-party verification option administered by Pollinator Partnership. The new third-party option administered by Where Food Comes From uses the same standards and support for farmers and ranchers to implement regenerative practices that help protect and promote pollinators. Participating farms implement practices to provide forage and nesting sites, avoid pesticide use by implementing Integrated Pest Management, improve soil health, increase carbon sequestration, elevate water quality, and ensure pollination efficacy.

08:10 EDT YanGuFang collaborates with China's R&D institution - YanGuFang International announced the establishment of the Collaborative Innovation Center for Whole Grain Seed Industry Technology in partnership with the China Jilin Baicheng Academy of Agricultural Sciences, an agricultural research institution in China pursuant to a strategic cooperation agreement the parties entered into. Under the Agreement, JBC agreed to contribute personnel with relevant technical expertise and its resources, including its germplasm technology, research capabilities, and its experimental fields. The Company agreed to contribute its industry expertise and fund the expenses related to crop breeding development and commercialization. Junguo He, the Chairman and CEO of the Company, commented, "We are excited to cooperate with JBC to establish the Center, which is expected to enhance breeding techniques and expedite the introduction of new and improved varieties of whole grain products to the market. Over the years, we have conducted a series of technological research and development of seed sources from the seed breeding and planting stages. Looking ahead, we anticipate the Center to actively engage in innovative breeding and commercialization of special grain crops, such as oat, buckwheat, and winter rye, in order to develop more products that suit the needs of our customers."

08:08 EDT Inari Medical announces planned enrollment of PEERLESS II trial - Inari Medical announced planned enrollment of the PEERLESS II trial, Inari's third randomized controlled trial in venous thromboembolism. The trial design was presented at the Society for Cardiovascular Angiography & Interventions 2023 Scientific Sessions. "PEERLESS II will build off Inari's FLASH registry, the largest prospective registry ever conducted in PE thrombectomy evaluating the FlowTriever System in 1,000 patients," said Dr. Thomas Tu, Inari's Chief Medical Officer. "With over 1,700 patients across PEERLESS and PEERLESS II, Inari is now set to enroll more PE RCT patients than all industry and non-industry RCTs combined. Inari's three RCTs in VTE all aim to study meaningful, patient-centric clinical endpoints. We are thankful for the partnership of our Steering Committee and the commitment of our investigators dedicated to generating high quality clinical evidence."

08:08 EDT Freddie Mac announces enhancements to automated income assessment tool - Freddie Mac announced enhancements to its ground-breaking automated income assessment tool that allows lenders to assess a homebuyer's income paid through direct deposit to also include the borrower's digital paystub data. This detailed information can help lenders calculate income faster and more precisely to improve loan quality, simplify the mortgage process and, most importantly, expand access to credit. The new ability to include paystub data in addition to direct deposit data in the income assessment is available to mortgage lenders nationwide through Freddie Mac's Loan Product Advisor asset and income modeler. AIM for income using direct deposit provides these cost-saving efficiencies while continuing to meet Freddie Mac's strong credit underwriting standards.

08:08 EDT Quantum Computing signs LOI to acquire AI platform millionways - Quantum Computing has signed a non-binding Letter of Intent - LOI - to acquire up to 100% of the AI firm, millionways, creator of the world's first emotionally-intelligent AI platform, pending the completion of due diligence by independent third party valuation and fairness opinion firms. The LOI follows the teaming and combining of millionways' AI sensing algorithms with QCI's quantum photonics computing power. Based in NY City, millionways develops AI algorithms used to effectively provide next-gen feedback to users on their emotional state and personality insights. Unlike other machine learning platforms such as ChatGPT, Alexa, or Siri, the millionways proprietary methodology and algorithms make behavorial predictions based on psychological patterns driven by underlying emotions. Over the past year, QCI has built and tested multiple hybrid AI hardware systems using photonics and quantum mechanics to boost machine learning efficiency, reduce the power consumption, and significantly speed up the training. QCI will provide a series of three bridge loans to millionways starting at $125K and potentially aggregating up to $2M, at QCI's discretion. Upon the completion of the first bridge loan, QCI will have the right of first refusal ("RoFR") to purchase millionways for a one-year period. Upon completion of the final bridge loan, QCI's RoFR will include a predetermined maximum valuation.

08:07 EDT Sangamo announces fast track designation from FDA for ST-920 - Sangamo announced that the FDA has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

08:07 EDT Xunlei downsizes domestic live streaming business - The company said, "Xunlei Limited is taking proactive measures to adjust certain business operations. Particularly, the Company is downsizing its domestic audio live streaming operations due to lower gross margin of such business and the rapidly evolving and challenging industry environment. As a result of this change, the Company expects that revenues from live streaming and other IVAS segment will be significantly reduced going forward. The Company will evaluate the impact of this initiative and provide an update on the second quarter revenue guidance in the near future."

08:06 EDT Venmo introduces Venmo Teen Account - Venmo introduced the Venmo Teen Account, providing parents and legal guardians the ability to open a Venmo account for their teenagers between the ages of 13 to 17-years-old so they can send and receive money. The Venmo Teen Account also comes with a Venmo Teen Debit Card. For the first time, the Venmo Teen Account gives teenagers a way to engage with and learn more about managing money through the Venmo app. The Venmo Teen Account will allow parents to monitor transactions, manage privacy settings, send money to their teen, and will help parents to educate their teens on creating healthy money habits. The Venmo Teen Account is rolling out to select customers from June 2023 and will be widely available in the coming weeks.

08:06 EDT Mizuho Financial Group to acquire Greenhill & Co. for $15 per share in cash - Mizuho Financial Group, Inc. (MFG) and Greenhill & Co., Inc. (GHL) announced a definitive agreement for Mizuho to acquire Greenhill in an all-cash transaction at $15 per share, reflecting an enterprise value of approximately $550M, including assumed debt. Through this transaction, Mizuho will accelerate its investment banking growth strategy, building on Greenhill's 27-year history of advising important clients on significant mergers & acquisitions, restructurings and capital raising transactions. Following completion of the transaction, Greenhill will operate globally from its 15 locations around the world as the M&A and restructuring advisory business of Mizuho. That business will maintain the Greenhill brand, and the existing Greenhill leadership team will remain in place. Greenhill Chairman & Chief Executive Officer Scott Bok will become Chairman of the M&A and restructuring advisory business. Current Greenhill Co-Presidents Kevin Costantino and David Wyles will become Co-Heads of the business. The Greenhill business will sit within Mizuho's banking division, led by Michal Katz, Head of Banking in the Americas. With this transaction, Mizuho will welcome Greenhill's 370 employees, as well as the valued client relationships they have built around the world. Both management teams are committed to a seamless transition for all clients and employees. The transaction is expected to close by year end and is subject to approval by Greenhill stockholders, as well as required regulatory approvals and other customary closing conditions.

08:04 EDT Chevron to acquire PDC Energy in $6.3B all-stock transaction - Chevron (CVX) announced that it has entered into a definitive agreement with PDC Energy, Inc. (PDCE) to acquire all of the outstanding shares of PDC in an all-stock transaction valued at $6.3B, or $72 per share. Based on Chevron's closing price on May 19 and under the terms of the agreement, PDC shareholders will receive 0.4638 shares of Chevron for each PDC share. The total enterprise value, including debt, of the transaction is $7.6B. The acquisition of PDC provides Chevron with assets expected to deliver higher returns in lower carbon intensity basins in the United States. PDC brings strong free cash flow, low breakeven production and development opportunities adjacent to Chevron's position in the Denver-Julesburg Basin, as well as additional acreage to Chevron's leading position in the Permian Basin. Chevron anticipates the transaction to be accretive to all key financial measures within the first year after closing and to add about $1B in annual free cash flow at $70 per barrel Brent and $3.50 per Mcf Henry Hub. Chevron expects to increase capex by about $1B per year, raising its guidance range to $14B to $16B through 2027, after realizing about $400M in capex efficiencies post-closing. The transaction is expected to achieve run-rate cost synergies of around $100M before tax within a year of closing. The acquisition consideration is structured with 100% stock utilizing Chevron's equity. In aggregate, upon closing of the transaction, Chevron will issue approximately 41M shares of common stock. Total enterprise value of $7.6B includes net debt. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close by year-end 2023. The acquisition is subject to PDC shareholder approval. It is also subject to regulatory approvals and other customary closing conditions. The transaction price represents a premium of 14% on a 10-day average based on closing stock prices on May 19.

08:04 EDT Chord Energy to acquire assets in the Williston Basin for $375M - Chord Energy (CHRD) announced that a wholly owned subsidiary of Chord has entered into a definitive agreement to acquire assets in the Williston Basin from XTO Energy (XTO) and affiliates, subsidiaries of Exxon Mobil (XOM) for total cash consideration of $375M, subject to customary purchase price adjustments. The consideration is expected to be funded with cash on hand, which was $592M as of March 31. The effective date of the acquisition is April 1, and the closing is expected to occur at the end of June, subject to customary closing conditions.

08:03 EDT Micron seeing some pockets of price stabilization, including DDR5 - Comments taken from the J.P. Morgan 51st Annual Global Technology, Media and Communications Conference.

07:39 EDT Starbox Group secures 3-year contract valued at $2.76M - Starbox Group announces that its Malaysian subsidiary, Starbox Rebates Sdn. Bhd., has entered into a software licensing agreement with 1 Pavilion Property Consultancy, a Kuala Lumpur-based company specializing in the sales and marketing of premium luxury properties. Pursuant to the Agreement, the Company has agreed to provide technology support with its unique, internally developed IT system to help 1Pavilion use the Company's data management system to better target customers and improve operational efficiency. The salient terms of the Agreement are as follows: i) The contract period shall be for three years, commencing May 18, 2023,and ending May 17, 2026; ii) The total contract sum during the Contract Period is RM12,400,000.00; and iii) The Company will grant 1Pavilion access to its data management system and will help train the staff of 1Pavilion with respect to its use. Lee Choon Wooi, Chief Executive Officer and Chairman of the Board of Directors of Starbox Group, commented, "We are delighted to have signed the Agreement with 1Pavilion, demonstrating our market recognition and providing us with technology driven income stream for the next three years. Being a tech-driven company, Starbox Group will continue to dedicate itself to research and development and technological innovation. We believe our newly developed technologies, such as data management and the A.I. Calculation Engine, will help 1Pavilion to scale its business and improve operational efficiency. Looking forward, we will keep upgrading our technology system to meet the demand of our clients across various industries, which is expected to boost our business and revenue growth in the long term."

07:36 EDT Asure Software added to Russell 3000 Index - Asure Software has been added to the preliminary list of additions to the broad-market Russell 3000 Index. Formal inclusion will be effective after the US market closes on June 23, as part of the 2022 Russell indexes reconstitution.

07:35 EDT Canopy Growth files proxy statement, modifies structure, for listing compliance - Canopy Growth has filed a revised proxy statement with the SEC, which includes updates related to its strategy to accelerate entry into the U.S. cannabis industry through a U.S.-domiciled holding company, Canopy USA. Upon receiving shareholder approval for the creation of a new class of non-voting exchangeable shares in the capital of Canopy Growth, Canopy USA is expected to exercise rights to acquire Acreage Holdings; Mountain High Products, , Wana Wellness, and The Cima Group, and Lemurian. In order to ensure continued compliance with NASDAQ's listing rules, Canopy Growth has modified the structure of the company's interest in Canopy USA such that it will not be required to consolidate the financial results of Canopy USA with the company's financial statements. Canopy USA is expected to leverage the best of each brand's offerings to accelerate growth and market expansion as key states across the country continue to allow recreational cannabis usage. The combination of U.S. cannabis assets is expected to generate revenue and cost synergies within Canopy USA by leveraging the brands, routes to market and operations of the full U.S. cannabis ecosystem while eliminating redundancies across certain of the Structured U.S. Investments and the public company reporting costs of Acreage.

07:33 EDT Sigilon Therapeutics announces 1-for-13 reverse stock split - Sigilon Therapeutics will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon's Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilon's Annual Meeting of Stockholders held on May 19, 2023. The reverse stock split is intended to increase the per share trading price of Sigilon's common stock to enable Sigilon to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market. Sigilon expects that upon the opening of trading on May 23, 2023, its common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the current trading symbol "SGTX" and the CUSIP number 82657L206.

07:32 EDT Cano Health board urges shareholders to vote on WHITE proxy card - Cano Health announced that it has filed its definitive proxy statement with the SEC and sent a letter to shareholders in connection with its upcoming Annual Stockholders' Meeting, which is scheduled for June 15. The Cano Health Board of Directors unanimously recommends that shareholders vote "FOR" each of the proposals listed on the WHITE proxy card enclosed with the definitive proxy statement-including the re-election of Dr. Alan Muney and Kim M. Rivera, and an amendment to the company's Certificate of Incorporation to authorize the company to consummate a reverse stock split. The proposed reverse split serves the best interests of all shareholders by, among other things, ensuring the company maintains compliance with the minimum stock price requirement for continued listing on the New York Stock Exchange.

07:20 EDT Mobilicom receives purchase order for its product solution - Mobilicom Limited announced it has received a purchase order for its end-to-end product solution from a leading global provider of autonomous and remote-controlled armor technology. "This purchase order marks the first in a line of expected orders for initial delivery to customers by our design-win partner, an armor and autonomous vehicle provider," said Mobilicom CEO and Founder Oren Elkayam. "By integrating multiple products into a turn-key bundle that is ready for deployment, we are achieving design wins, and purchase orders, and Mobilicom is building a platform for wider commercial-scale shipments."

07:20 EDT Avalo Therapeutics appoints Croft, Edelson to SAB - Avalo Therapeutics announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company's Scientific Advisory Board, SAB. The SAB, which is led by Dr. Carl Ware, provides strategic and scientific guidance to Avalo as it progresses its pipeline of therapies that target the LIGHT-signaling network, notably AVTX-002 and AVTX-008.

07:18 EDT Correction: Athira Pharma did not report Scientific Advisory appointments

07:15 EDT NeuBase Therapeutics announces data for its Stealth Editors development - NeuBase Therapeutics announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system. These preclinical data were featured in an oral presentation by Dr. Dani Stoltzfus, Vice President of Research at NeuBase, titled, "Nuclease-Free Gene Editing with Peptide Nucleic Acids: A New Class of In Vivo Gene Editors," at the ASGCT 2023 Annual Meeting. "We are excited to announce preclinical data from our Stealth Editors development program that were presented during the ASGCT 2023 Annual Meeting. These data support our novel in vivo gene editing approach that allows us to tag a locus in the genome that harbors a mutation with a simple synthetic compound and recruit the cell's own machinery to repair the mutation. This high-fidelity non-immunogenic approach is expected to offer advantages compared to modified bacterial CRISPR/Cas enzymes for in vivo gene editing applications from a safety and durability of effect perspective," stated Dietrich A. Stephan, Ph.D., Founder and Chief Executive Officer of NeuBase. "We continue to rapidly advance the development of our Stealth Editors platform, which we believe has the potential to generate best-in-class, next-generation therapies capable of addressing diverse types of high-value genetic mutations. Throughout the remainder of 2023, we expect to announce additional preclinical data from several ongoing and planned studies in non-human primates and mice."

07:14 EDT Plug Power lands three five megawatt electrolyzer projects - Plug Power landed three five megawatt electrolyzer projects with Ardagh Glass Limmared AB, Hydro Havrand, and the APEX Group for the first-ever use of industrial-scale green hydrogen in glass manufacturing, aluminum recycling, and steel manufacturing processes. Green Glass Manufacturing: Ardagh will produce 2.1 metric tons per day of green hydrogen by the end of the year, replacing a portion of the natural gas used today while reducing overall carbon emissions at the plant. Ardagh will use hydroelectric power to generate hydrogen from Plug's electrolyzer. Aluminum Recycling: Hydro Havrand, a new unit of aluminum giant Norsk Hydro ASA, is on a mission to decarbonize heavy industry with green hydrogen. Hydro will employ a 5MW Plug electrolyzer module by June 2024. Green Steel Manufacturing: In Bremen, Germany, Plug and its trusted partner APEX Group, an integrator with strong project execution expertise, will demonstrate for the first time the feasibility of producing green steel through the decarbonization of ArcelorMittal's local blast furnaces. Plug will deliver two 5MW electrolyzer modules with a capacity to produce 4.2 metric TPD of green hydrogen to SWB, the city's public utility company, by the end of this year.

07:12 EDT Milestone Pharmaceuticals presents data of etripamil nasal spray - Milestone Pharmaceuticals announced 'promising' data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate - AFib-RVR - in the NODE-303 study, which evaluated etripamil, the company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia. Results demonstrate a maximum reduction of -27.4 +/- 6.1 bpm at 22 minutes, and -16.2 +/- 5.6 bpm at 60 minutes. The safety and tolerability data from the analysis of these AFib-RVR episodes were consistent with those observed across prior studies in PSVT. Overall, the majority of AEs were reported as mild to moderate, and there were no reported serious AEs related to etripamil. Enrollment continues in ReVeRA, Milestone's Phase 2 double-blind, placebo-controlled, proof-of-concept trial of etripamil nasal spray in emergency-department patients experiencing AFib-RVR. The trial is designed to assess the safety and efficacy of etripamil nasal spray to reduce elevated ventricular rates in patients with symptomatic AFib-RVR. The primary endpoint will assess reduction in ventricular rate, with key secondary endpoints including the time to achieve the maximum reduction in rate and duration of the effect. Milestone expects to report topline data from this trial in the second half of 2023.

07:10 EDT Castle Biosciences announces new laboratory facility in Pittsburgh - Castle Biosciences announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh. "Castle is proud to be a member of the Pittsburgh community and grow our footprint in this great city," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Our new state-of-the-art laboratory provides us with additional capacity that should allow us to continue to scale our operations in the future. We are excited about the opportunities this new space provides for the growth of our business as well as for our continued impact on patient care." The new 20,000-square-foot facility doubles the size of Castle's previous Pittsburgh laboratory and is located in the city's historic North Side, in the Nova Place complex at 100 S. Commons, Suite 245. Castle expects to have the capacity and ability to process each of its proprietary tests out of the new laboratory. Additionally, Castle is anticipating doubling its workforce in the city, creating approximately 35 new jobs by the end of 2023, including histotechnologist and molecular technologist positions and other jobs in a variety of areas, including laboratory operations, research and development, and information technology. Castle operates clinical laboratories in Pittsburgh and Phoenix. The Company's laboratories are College of American Pathologists CAP accredited and Clinical Laboratory Improvement Amendments CLIA certified, reflecting the Company's commitment to high-quality standards and excellence in patient care. The new laboratory in Pittsburgh brings Castle's total laboratory operations space to more than 52,000 square feet combined.

07:10 EDT Tingo Group set to join Russell 3000 Index - Tingo Group announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 FTSE Russell indexes annual reconstitution process, which is effective after the U.S. markets close on June 23, 2023 according to a preliminary list of additions announced on May 19, 2023.

07:09 EDT Immunovant expects cash to fund operations into 2H25 - As of March 31, 2023, Immunovant's cash and cash equivalents totaled $376.5 million, which is expected to fund operations into the second half of calendar year 2025.

07:07 EDT ZIM Integrated still sees 2023 adjusted EBITDA $1.8B-$2.2B

07:07 EDT Avrobio to sell HSC gene therapy program to Novartis for $87.5M in cash - Avrobio (AVRO) announced an agreement to sell its investigational hematopoietic stem cell, or HSC, gene therapy program for the treatment of cystinosis to Novartis (NVS) for $87.5M in cash. Avrobio retains full rights to its portfolio of HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease. Proceeds from this transaction are expected to extend the company's cash runway into the fourth quarter of 2024. Pursuant to the terms of an asset purchase agreement, Novartis will pay Avrobio $87.5M in cash at closing, in consideration for the sale and transfer of certain assets related to the cystinosis program. In addition, Avrobio has exclusively licensed to Novartis certain other assets, know-how and other intellectual property related to Avrobio's gene therapy platform for use in cystinosis. To support the transition of the program, Avrobio also has agreed to provide under a separate agreement certain transition, knowledge transfer and other related services.

07:06 EDT HUB Security gets notice from Nasdaq related to delated filing of 2022 report - HUB Cyber Security announced, as expected, that it has received a notice from The Nasdaq Stock Market indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC . The Notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on Nasdaq, subject to the Company's compliance with the other continued listing requirements of Nasdaq. As previously disclosed, a special committee of independent directors of the Company's Board of Directors ("Special Committee") is working to complete its investigation into unexplained expenses incurred by a former senior officer of the Company and, as such, the Company requires additional time to file the Annual Report.

07:05 EDT BioCryst announces approval for ORLADEYO by ISP of Chile - BioCryst Pharmaceuticals announced that the Public Health Institute, ISP, of Chile has granted marketing authorization for oral, once-daily ORLADEYO for the prophylaxis of hereditary angioedema attacks in patients 12 years of age or older. "Today's announcement marks the first approval of ORLADEYO in Latin America, which is an important step forward in addressing the significant unmet needs of hereditary angioedema patients who live in the region. With this approval, we continue our mission to bring ORLADEYO to patients around the world who could benefit from an oral, once-daily prophylactic treatment option to improve control of their HAE attacks," said Charlie Gayer, chief commercial officer of BioCryst.

07:02 EDT Hepion Pharmaceuticals Phase 2 ALTITUDE-NASH trial achieves primary endpoint - Hepion Pharmaceuticals announced positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial. ALTITUDE-NASH met its primary endpoint by demonstrating improved physiologic liver function and was well tolerated after four months of treatment in subjects with stage 3 or greater fibrosis based on the AGILE 3+ criteria. All additional secondary endpoints were also met, including reductions in the liver injury biomarkers, alanine and aspartate transaminases; and multiple fibrosis-associated biomarkers, including ProC3, PIIINP, TIMP1, hyaluronic acid, and enhanced liver fibrosis scores. These observations build on similar findings from a shorter Phase 2a trial and reinforce rencofilstat's direct antifibrotic mode of action and increase the confidence for reductions in fibrosis in Hepion's ongoing Phase 2b ASCEND-NASH paired biopsy trial. "We are thrilled that the ALTITUDE-NASH trial met both its primary efficacy and safety endpoints, in particular with the 225 mg rencofilstat dose showing the greatest benefit to liver function and multiple NASH-associated biomarkers," said Todd Hobbs, MD, Hepion's Chief Medical Officer. "This trial was designed to inform us on how well rencofilstat improves hepatic function in those with significant impairment and risk for complications from their advanced NASH. Further, it provided an opportunity to evaluate data generated from different doses of rencofilstat. I am very pleased with the research team and the ALTITUDE-NASH sites that quickly recruited this study. Our improved understanding of which subjects best respond to rencofilstat can be immediately applied to increase the likelihood of success of our larger and longer ASCEND-NASH paired biopsy trial."

07:02 EDT Ironwood to acquire VectivBio for $17.00 per share in cash, or about $1B - Ironwood Pharmaceuticals (IRWD) and VectivBio (VECT) announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1B, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days. The Transaction was approved by both the Ironwood and VectivBio Boards of Directors and the Transaction Agreement was entered into on May 21, 2023. The Transaction is conditioned upon, among other things, the tender of shares representing more than 80% of VectivBio's issued and outstanding shares and other customary conditions. Orbimed, Forbion and Versant Ventures, and VectivBio's directors and officers, jointly representing 28.6% of VectivBio's shareholdings, entered into tender and support agreements pursuant to which such supporting shareholders agreed, among other things, to tender their shares in the tender offer. The Transaction, which was approved by each company's Boards of Directors, is expected to close in the second half of 2023, subject to the Offer Conditions. Ironwood anticipates the pro forma company will remain positioned to deliver sustained profits and cash flows. Ironwood expects to generate greater than $175M in operating cash flows each year on a pro forma basis ahead of apraglutide commercial launch. The Transaction, assuming successful commercialization of apraglutide, is expected to be accretive to earnings per share beginning in 2026.

06:56 EDT European Wax Center names Andrea Wasserman as Chief Commercial Officer - European Wax Center (EWCZ) announced the appointment of Andrea Wasserman as Chief Commercial Officer effective May 30. Most recently, Wasserman was a Managing Director for Connected Commerce at JPMorgan Chase (JPM) where she focused on growing revenue via B2C marketing and B2B partnerships.

06:46 EDT Alarm.com acquires Polish security communicator manufacturer EBS - Alarm.com has acquired EBS, a specialist in the design and manufacturing of smart communicators that are widely deployed in international markets. EBS technology complements Alarm.com's software solutions. Integrating with EBS smart communicators will expand Alarm.com's support for legacy security control panels that are widely deployed in international markets. EBS was founded over 30 years ago. EBS will continue to operate independently and the current management team at EBS will lead the business from its headquarters in Warsaw, Poland, and maintain a manufacturing facility in Elk, Poland.

06:33 EDT EnergySource Minerals, Ford announce binding lithium supply contract - EnergySource Minerals, or ESM, announced a binding lithium supply contract with Ford. ESM will supply Ford with lithium hydroxide produced at ESM's Project ATLiS, located in Imperial Valley California. Project ATLiS is expected to be operational in 2025. Using only a fraction of the carbon, water and land footprint of any other operation in the world, Project ATLiS aims to set a new standard in sustainable lithium production. The project will maximize lithium output in a closed-loop environment and aims to deliver significant reduction in time, cost and environmental impact compared with alternative approaches. The operation will feature ESM's breakthrough ILiAD technology platform, which separates lithium from an underlying geothermal brine resource, in an efficient and sustainable way.

06:17 EDT Ford sees Model e's growth production capacity run-rate of 2M EVs by 2026 end - Ford Model e's growth expectations include a production capacity run-rate of 2M EVs by the end of 2026 and beyond. To that end, Drake will announce Ford's latest agreements for battery raw materials at the company's capital markets day.

06:05 EDT Missfresh receives Nasdaq notification regarding late filing of Form 20-F - Missfresh announced that it received a notification letter dated May 18 from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the company is not in compliance with the filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) since the company did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the SEC.

06:04 EDT Western Midstream announces sanctioning of new cryogenic plant - Western Midstream Partners announced the sanctioning of a new 250 MMcf/d cryogenic processing plant in the North Loving area of its West Texas complex. The expected in-service date is the end of Q4 2024. Concurrent with the sanctioning of the North Loving Plant, WES updated 2023 guidance: total capital expenditures are now expected to be $700.0M-$800.0M, a $125.0M increase to the midpoint of prior guidance. Free cash flow is expected to be $1.0B-$1.1B, a $125.0M decrease to prior guidance. WES is maintaining its 2023 Adjusted EBITDA guidance range of $2.05B-$2.15B, and its full-year 2023 Base Distribution of at least $2.00 per unit, which excludes the impact of any potential Enhanced Distribution.

05:39 EDT Meta appealing Irish Data Protection decisions, calls fine 'unjustified' - Meta Platforms said in a statement, "Today, the Irish Data Protection Commission has set out its findings into Meta's use of this common legal instrument to transfer Facebook user data between the EU and the US. Despite acknowledging we had acted in good faith and that a fine was unjustified, the DPC was overruled at the last minute by the European Data Protection Board. We are appealing these decisions and will immediately seek a stay with the courts who can pause the implementation deadlines, given the harm that these orders would cause, including to the millions of people who use Facebook every day...Ultimately, the invalidation of Privacy Shield in 2020 was caused by a fundamental conflict of law between the US government's rules on access to data and the privacy rights of Europeans. It is a conflict that neither Meta nor any other business could resolve on its own. We are therefore disappointed to have been singled out when using the same legal mechanism as thousands of other companies looking to provide services in Europe....Without the ability to transfer data across borders, the internet risks being carved up into national and regional silos, restricting the global economy and leaving citizens in different countries unable to access many of the shared services we have come to rely on." Reference Link

05:31 EDT Boeing announces order for up to four premium BBJ from undisclosed customers - Boeing announced orders for up to four premium, ultra-long-range Boeing Business Jets, or BBJ. The orders to undisclosed VIP customers include two BBJ 787-8s, one BBJ 737-7 jet and an option to purchase a BBJ 777-9. The company shared the 2023 orders at the European Business Aviation Convention & Exhibition, or EBACE, in Switzerland.

05:26 EDT Vertical Aerospace announces Kakao Mobility pre-orders up to 50 VX4 aircraft - Vertical Aerospace announced that South Korean mobility technology company, Kakao Mobility, has pre-ordered up to 50 of Vertical's VX4 aircraft, adding South Korea to Vertical's list of customer launch markets. Vertical and Kakao Mobility will establish a Joint Working Group, or JWG, to drive the commercialization of AAM services in South Korea, including the exploration of network and fleet planning, infrastructure requirements, regulatory development, and consumer awareness of eVTOL mobility solutions.